ASX ANNOUNCEMENT **13 November 2026**

Update on Proposed Placement and Corporate Activities

Key Points

- ***General Meeting of shareholders to be held in January 2027 to seek approval of proposed Placement, which is now expected to raise ~$750k before costs***
- ***Placement terms are the same as the recently completed Entitlement Offer, which raised ~$913k before costs***
- ***If Placement is approved by shareholders, total amount raised under the Placement and Entitlement Offer will be ~$1.663m before costs***
- ***Company update:***
  - ***All material costs relating to recently completed Cymerus™ clinical trials and termination of employee and service provider agreements have been paid***
  - ***The Cymerus™ intellectual property portfolio, including license agreements, patents and cell lines, is being maintained***
  - ***The externally funded Phase 1/2 NEREID kidney transplant trial of CYP-001 is still ongoing, with the three patients in the second cohort undergoing follow-up after treatment***
  - ***The Board is evaluating options for further development of the Cymerus™ technology, as well as a number of opportunities to obtain rights to new assets***

Melbourne, Australia; 13 November 2026: Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company") provides an update on its proposed Placement, originally announced on 4 November 2026, as well as an update on the Company's activities.

Placement

On 4 November 2026, the Company announced that the Underwriter of its recently completed pro rata entitlement offer of $912,953.88 before costs ("**Entitlement Offer**"), Caravel Securities Pty Ltd ACN 655 357 915 (**"Carasec"**), had received firm commitments for a placement of approximately 55 million new, fully paid ordinary shares (**"Placement Shares"**) at an offer price of $0.01 per Placement Share (the same offer price as the Entitlement Offer), to raise ~$550,000 before costs.

The Company is pleased to announce that Carasec has now received firm commitments for an additional ~$200,000 worth of Placement Shares (representing ~20 million Placement Shares), resulting in a Placement which will raise a total of ~$750,000 via the issue of ~75 million Placement Shares (subject to shareholder approval).

As with the Entitlement Offer, one free attaching option (**"Attaching Option"**) will be issued for every three Placement Shares issued. The Attaching Options will have the same terms as the Entitlement Options issued under the Entitlement Offer, including an exercise price of $0.02 and an expiry date of 3 May 2029. Carasec will act as lead manager for the Placement, and will receive a placement fee equal to 6% of the amount raised under the Placement and 8,200,000 options to acquire Shares in the Company (**"Placement Fee Options"**). The number of Placement Fee Options has been increased from 6,000,000 (as announced on 4 November 2026) to 8,200,000 given the increased size of the Placement. The terms of the Placement Fee Options will be the same as the terms of the Attaching Options issued under the Placement. The Placement (including the issue of Placement Shares and Attaching Options) and the issue of the Placement Fee Options will be

subject to shareholder approval, which will be sought at a General Meeting (**"GM"**), which is expected to be held in January 2027. Details of the GM will be communicated in the coming weeks.

The Company has taken the decision to increase the size of the Placement in light of interest from sophisticated investors. The proceeds of the Placement will be used to provide the Company with greater flexibility to pursue potential transactions to secure rights to new assets, in addition to paying for the costs of the Placement and providing further working capital, consistent with the use of funds outlined in the Replacement Prospectus released on 12 October 2026. None of the additional ~20 million Placement Shares will be issued to related parties.

Company Update

All material costs relating to recently completed Cymerus™ clinical trials and termination of employee and service provider agreements have been paid (refer to the announcement of 6 July 2026 for background). The Company is continuing to maintain its Cymerus™ intellectual property portfolio, including license agreements, patents and cell lines.

The Phase 1/2 NEREID kidney transplant trial, which is being managed and funded by Leiden University Medical Centre (LUMC) in the Netherlands, is still ongoing, with enrolment and treatment of the second cohort of patients now complete. As announced on 4 December 2025, the independent Data and Safety Monitoring Board (DSMB) review of the first cohort of patients in this trial found no episodes of kidney transplant rejection and no safety concerns. The three patients in the first cohort each received a single infusion of CYP-001,[1] in addition to standard treatment. In the second cohort of the trial, a further three patients each received two infusions of CYP-001, in addition to standard treatment. A DSMB review of the second cohort will take place when the final patient in the second cohort has been followed up for six weeks after receiving the second infusion of CYP-001. The Company will announce the results of the DSMB review once they are received from LUMC.

The novel Cymerus™ platform technology continues to offer a genuinely differentiated approach to manufacturing mesenchymal stromal cells (MSCs) at commercial scale from a single, consistent cell source, and the Board is evaluating options for its further development.

Additionally, an important component of the Company's strategy is to identify opportunities to acquire, in-license or otherwise obtain rights to new pharmaceutical or biotechnology assets or development programs.

-ENDS-

Authorised for release by the Board of Directors

CONTACT: investors@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited's (ASX: CYP) core asset is currently the Cymerus™ platform, which offers a genuinely differentiated approach to manufacturing mesenchymal stromal cells at commercial scale from a single, consistent cell source. The Board is now focused on evaluating the future development pathways available for this technology, and the broader strategic options open to the Company. This includes seeking opportunities to realise value from the Cymerus™ technology and obtaining rights to new assets.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Pty Ltd.

[1] CYP-001 is Cynata's Cymerus™ induced pluripotent stem cell (iPSC)-derived mesenchymal stromal cell (MSC) product candidate for intravenous use.